Clinical Trial

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Study acronym: RAISE-XT
Completed Phase 3
View on ClinicalTrials.gov →
Summary
The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.
Protocol Amendment History 1 change
critical Trial completed 2026-08-13
Trial Details
NCT Number NCT04225871
Lead Sponsor UCB Biopharma SRL
Conditions Generalized Myasthenia Gravis
Enrollment 200 participants
Start Date 2019-12-23
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-12